Ann: AstraZeneca extends and increases Renal Contract, page-4

Eddy Sunarto
On March 18, 2022
ASX Health Stocks: ImpediMed extends SOZO contract with global pharma AstraZeneca

• ImpediMed extends SOZO contract with AstraZeneca

The ASX 200 Health Index (XHJ) is trading lower by 0.65% at the time of writing, compared to the broader index which is up by 0.25%.

The Phase 2 trial was designed to study the efficacy, safety, and tolerability of a combination of two AstraZeneca drugs in patients with chronic kidney disease – and is expected to be completed in August.

The number of SOZO devices used in the study has increased from 200 to 223, and the contracts are expected to generate over $5.5 million in revenue across the trials.

ImpediMed has recognised approximately $3.5 million in revenue under these contracts through 31 December 2021, and the remainder will be recognised throughout the second half of FY’22 and first half of FY23.

SOZO is said to be the world’s most advanced, noninvasive BIS (bioimpedance spectroscopy) device, giving doctors a precise snapshot of fluid status and tissue composition in less than 30 seconds.

“To date, the feedback on SOZO has been very positive,” said ImpediMed CEO, Richard Carreon.

“This trial is providing a significant number of cardiologists and nephrologists, both in the US and globally, firsthand experience with SOZO,” he added.